GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Altamira Therapeutics
Altamira is a biotech company developing drugs for ear and nose diseases. Its stock price is volatile and dependent on clinical trial results. The chart reflects investor hopes for a breakthrough in these complex areas.
Share prices of companies in the market segment - Pharma other
Altamira Therapeutics is a Swiss biopharmaceutical company developing drugs for the treatment of inner ear diseases and viral infections. We classified it in the "Other Pharmaceuticals" category. The chart below shows how investors value companies with a diversified pipeline.
Broad Market Index - GURU.Markets
Altamira Therapeutics is a Swiss biopharmaceutical company developing medications for ear, nose, and throat diseases, as well as antiviral treatments. Its unique specialization makes it a prominent player in the GURU.Markets index. The chart below represents the entire market. Find out how Altamira compares to it.
Change in the price of a company, segment, and market as a whole per day
CYTO - Daily change in the company's share price Altamira Therapeutics
Altamira Therapeutics Ltd.'s daily price change reflects the high volatility inherent in biotech companies. This indicator measures its sensitivity to news about clinical trials of its ear and nose treatments.
Daily change in the price of a set of shares in a market segment - Pharma other
Altamira Therapeutics develops drugs to protect against viral infections and treat tinnitus. These are highly specialized and risky niches in the pharmaceutical industry. The chart below shows the volatility in this sector, reflecting the high stakes associated with new drug development.
Daily change in the price of a broad market stock, index - GURU.Markets
Altamira is a Swiss biotech company. Its US-listed shares bring the dynamics of the European biotech sector to the market. These international factors make the overall picture of market volatility more complex and global.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Altamira Therapeutics
For Altamira Therapeutics, its year-over-year performance tells the story of its strategic pivot. Its 12-month market cap change reflects its decision to focus on developing RNA-based drugs, particularly for cancer, after selling its earlier assets. Its valuation is a bet on success in a new, promising field.
Annual dynamics of market capitalization of the market segment - Pharma other
As an early-stage biotech company, Altamira is a high-risk bet on science. Its performance is completely disconnected from the sector and depends on news about the clinical trials of its drugs. Its stock price will reflect investors' speculative belief in the potential of its unique developments.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Altamira Therapeutics, with its diverse development pipeline, is a complex biotech story. Its performance relative to the market reflects investors' assessment of the likelihood of success on multiple fronts. Advances in any of these areas, whether RNA therapeutics or ear drops, could be a powerful growth catalyst.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Altamira Therapeutics
Altamira is a biopharmaceutical company with a diversified portfolio. Its monthly performance reflects the combined impact of news across its various programs, from ear medications to nasal sprays. Progress in any of these programs can impact its valuation.
Monthly dynamics of market capitalization of the market segment - Pharma other
Altamira Therapeutics develops drugs to treat inner ear disorders such as hearing loss and tinnitus. This is an area with a huge unmet need. The dynamics of the biotech sector underscore the overall context in which Altamira is attempting to create a first-of-its-kind drug, addressing a problem that affects millions of people worldwide.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Altamira Therapeutics Ltd. is a biopharmaceutical company developing drugs for the treatment of inner ear disorders such as hearing loss and tinnitus, as well as nasal sprays. The company's future depends on the success of its clinical trials. The broader market chart serves only as a backdrop to understand how its scientific milestones and regulatory decisions have impacted its stock.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Altamira Therapeutics
Altamira Therapeutics is a clinical-stage biopharmaceutical company focused on developing drugs for inner ear diseases and nasal sprays. Its weekly stock price is volatile and dependent on clinical trial news.
Weekly dynamics of market capitalization of the market segment - Pharma other
Altamira Therapeutics is working in the field of RNA therapeutics, developing drugs to treat a variety of diseases. This is a cutting-edge, but risky, technology. The chart below will help determine whether Altamira's share price fluctuations are a reaction to its own scientific data or reflect the general hopes and concerns surrounding the entire RNA platform.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Altamira is an early-stage pharmaceutical company. Its shares are trading in anticipation of research results. The chart clearly shows how much their performance is driven by scientific news and regulatory decisions, rather than by general market trends.
Market capitalization of the company, segment and market as a whole
CYTO - Market capitalization of the company Altamira Therapeutics
Altamira Therapeutics' market capitalization chart tells the story of a biotech struggling to find its niche. Its volatile chart reflects its shifts between different areas, from ear diseases to viral defense. Its low valuation reflects investor skepticism, as investors await compelling clinical data.
CYTO - Share of the company's market capitalization Altamira Therapeutics within the market segment - Pharma other
Altamira Therapeutics is a company developing drugs for the treatment of ENT diseases and viral infections. Its market share in the pharmaceutical sector is very small. Its market capitalization reflects investors' assessment of its research programs and is an indicator of progress in clinical trials, not current commercial success.
Market capitalization of the market segment - Pharma other
The chart below shows the overall value of the biotech sector. Altamira Therapeutics is developing drugs to treat inner ear disorders such as hearing loss and vertigo, as well as nasal sprays to protect against viruses. Its diversified approach, relative to the market, is an attempt to solve several complex medical problems simultaneously.
Market capitalization of all companies included in a broad market index - GURU.Markets
Altamira Therapeutics develops drugs to treat inner ear disorders such as dizziness and hearing loss, as well as nasal sprays to protect against viruses. Its market capitalization reflects this diversification. The chart below shows the weightings of companies in this profile.
Book value capitalization of the company, segment and market as a whole
CYTO - Book value capitalization of the company Altamira Therapeutics
Altamira's book value is derived from its intellectual property (IP) in its portfolio of drugs for the treatment of inner ear disorders (hearing loss, tinnitus) and upper respiratory tract disorders (nasal sprays). The chart tells the story of a biotech company diversifying its assets, developing products in different but related areas.
CYTO - Share of the company's book capitalization Altamira Therapeutics within the market segment - Pharma other
Altamira Therapeutics develops RNA therapeutics. The chart shows its share of actual R&D assets. These include its laboratories where oligonucleotide delivery platforms are created, which provide the scientific foundation for this new class of drugs.
Market segment balance sheet capitalization - Pharma other
Altamira Therapeutics develops drugs for the treatment of inner ear and upper respiratory tract diseases. Their business is R&D. The book value chart shows their laboratory base, which represents only a small portion of their potential value derived from R&D.
Book value of all companies included in the broad market index - GURU.Markets
Altamira Therapeutics' assets include laboratories and R&D centers developing drugs for inner ear diseases and nasal sprays. The chart shows how the company's scientific and material assets have changed over the course of its research.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Altamira Therapeutics
Altamira Therapeutics develops drugs for ENT diseases and other conditions. Its tangible assets are insignificant. The chart below visualizes market expectations. Its dynamics are directly linked not to plant growth, but to news about clinical trials and potential partnerships that could turn science into money.
Market to book capitalization ratio in a market segment - Pharma other
Altamira Therapeutics develops drugs to treat ear, nose, and throat conditions, such as hearing loss and allergies. The company's valuation is based on the potential of its scientific developments. The chart shows how its market capitalization, driven by hopes for success in these complex areas, relates to its current tangible assets.
Market to book capitalization ratio for the market as a whole
Altamira Therapeutics develops new drug delivery methods. Like many biotechs, its value lies in its research and patents. This chart demonstrates that its market valuation is based on the expected future commercial success of its platforms, not the cost of laboratory equipment, resulting in a high valuation.
Debts of the company, segment and market as a whole
CYTO - Company debts Altamira Therapeutics
Altamira Therapeutics develops various therapeutic platforms, including antiviral sprays and tinnitus treatments. This chart shows how the company finances its diversified but risky portfolio of projects. Funding is provided through equity capital.
Market segment debts - Pharma other
Altamira Therapeutics develops innovative drug delivery methods, particularly for the treatment of ear and nose diseases. This is a niche area of pharmacology that requires specific research. This chart reflects the company's financial strategy for commercializing its unique technology platforms.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Altamira Therapeutics
Altamira Therapeutics is a biopharmaceutical company with several projects in development. This chart shows its financial structure. For a company pursuing several risky projects simultaneously, a strong balance sheet is essential. Debt increases the overall risk for investors.
Market segment debt to market segment book capitalization - Pharma other
Altamira Therapeutics is a biopharmaceutical company developing drugs for the treatment of ear, nose, and throat diseases. This chart shows the debt burden in the biotech sector. It is an indicator of the company's ability to finance its highly specialized and risky clinical programs.
Debt to book value of all companies in the market
Altamira Therapeutics develops drugs for the treatment of inner ear and upper respiratory tract diseases. These are highly specialized areas that require focused research. This graph of total market debt helps assess the company's ability to attract funding for its niche but important clinical programs.
P/E of the company, segment and market as a whole
P/E - Altamira Therapeutics
Altamira Therapeutics is a Swiss biotech company developing RNA therapeutics to protect against viral infections and treat cancer. This graph reflects the high risk and potential of biotech developments. Its dynamics depend on success in clinical trials and strategic partnerships.
P/E of the market segment - Pharma other
Altamira Therapeutics is a biotech company developing therapeutics for inner ear disorders (hearing loss, tinnitus), as well as antiviral and antiallergy nasal sprays. This chart shows the average valuation for the pharmaceutical sector, reflecting how investors value companies with a diversified pipeline.
P/E of the market as a whole
Altamira Therapeutics is a Swiss biopharmaceutical company developing treatments for ear, nose, and throat diseases. Its valuation depends entirely on the success of its drugs in clinical trials and regulatory approval. Overall market sentiment, reflected in this chart, is completely irrelevant.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Altamira Therapeutics
Altamira Therapeutics is a Swiss biopharmaceutical company developing drugs for the treatment of ear, nose, and throat diseases, as well as RNA therapeutics. This chart reflects market expectations for the success of its diversified development pipeline. Future revenue depends on the results of clinical trials in various areas.
%20P%2FE%20Altamira%20Therapeutics&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Altamira-Therapeutics&v=1772595773730 "Chart of the company's future (projected) P/E Altamira Therapeutics")
Future (projected) P/E of the market segment - Pharma other
Altamira Therapeutics is developing RNA therapeutics to protect against viral infections and treat cancer. This chart shows general expectations for the biotech sector. CYTO's position relative to the average reflects how the market views their innovative RNA delivery platform and the potential of their candidates to treat a variety of diseases, from the common cold to cancer.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Pharma%20other&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Pharma-other&v=1772595773737 "Future (projected) P/E graph of the market segment - Pharma other")
Future (projected) P/E of the market as a whole
Altamira Therapeutics is a Swiss biopharmaceutical company developing RNA-based therapies for viral protection (e.g., a nasal spray) and the treatment of dizziness. The company is working in several therapeutic areas. This chart of general market expectations provides a framework for evaluating biotech companies with a diversified but risky early-stage pipeline.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772595773744 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Altamira Therapeutics
Altamira Therapeutics is a biopharmaceutical company developing drugs for the treatment of inner ear disorders (hearing loss, dizziness) and intranasal sprays. Its financial schedule reflects the costs of clinical trials of various programs. Future profitability depends on the success of one of its candidates.
Profit of companies in the market segment - Pharma other
Altamira Therapeutics is developing RNA-based therapies to protect against viral infections (e.g., a nasal spray) and treat dizziness. These are innovative but risky projects. This chart shows the overall profitability of its pharmaceutical segment. It illustrates the industry's success in creating and commercializing breakthrough, yet unproven, medical solutions.
Overall market profit
Altamira Therapeutics develops medications for inner ear disorders such as hearing loss and vertigo, as well as protective nasal sprays. These are niche markets where success depends on the effectiveness of their products. The positive economic situation, reflected in this chart, facilitates the company's ability to raise funds for clinical trials and marketing.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Altamira Therapeutics
Altamira Therapeutics develops medications for the treatment of inner ear disorders, such as dizziness and hearing loss, as well as nasal sprays. Future profits depend on the success of its developments. This chart shows analyst expectations for the commercial potential of its niche otolaryngology products.
%20profit%20of%20the%20company%20Altamira%20Therapeutics&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Altamira-Therapeutics&v=1772595773876 "Graph of future (projected) profit of the company Altamira Therapeutics")
Future (predicted) profit of companies in the market segment - Pharma other
Altamira Therapeutics develops drugs to treat inner ear disorders such as dizziness and hearing loss, as well as to protect against viral upper respiratory infections. This chart shows forecasts for the entire pharmaceutical sector, helping to assess Altamira's potential to address these common yet complex medical problems and challenges.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Pharma%20other&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Pharma-other&v=1772595773903 "Graph of future (predicted) profits of companies in a market segment - Pharma other")
Future (predicted) profit of the market as a whole
Altamira Therapeutics develops medications for inner ear diseases and nasal sprays. The company's success depends on the results of clinical trials and product commercialization. The overall economic forecasts shown in this chart are of minimal significance for the company at this stage.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772595773934 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Altamira Therapeutics
Altamira Therapeutics develops drugs to treat inner ear disorders such as hearing loss and tinnitus. This chart reflects the market's valuation of its innovative, yet risky, developments. The trend reflects investor confidence in the company's ability to succeed in areas of medical need.
P/S market segment - Pharma other
Altamira Therapeutics develops drugs to treat inner ear disorders such as hearing loss and vertigo, as well as other RNA-based therapies. Future revenue depends on the success of these developments. This pharma-specific chart reflects investor expectations for Altamira's potential to solve complex problems in otology and beyond.
P/S of the market as a whole
Altamira Therapeutics is a biopharmaceutical company developing drugs to treat inner ear disorders (hearing loss, dizziness), as well as nasal sprays for protection against viruses and allergens. This market revenue valuation chart helps understand how investors value the company's diversified portfolio, which targets different markets.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Altamira Therapeutics
Altamira Therapeutics is a Swiss biotech company developing drugs to treat inner ear disorders such as hearing loss and tinnitus, as well as nasal sprays to protect against viruses. This chart shows how investors assess the future commercial potential of its diverse product portfolio, betting on research success.
%20P%2FS%20Altamira%20Therapeutics&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Altamira-Therapeutics&v=1772595774024 "The graph of the company's future (projected) P/S Altamira Therapeutics")
Future (projected) P/S of the market segment - Pharma other
Altamira Therapeutics is a biotech company developing RNA-based therapies for viral infections and cancer treatment, as well as drugs for inner ear diseases. The company's valuation reflects investors' views on the potential of its diverse, yet early-stage pipeline across various therapeutic areas.
%20P%2FS%20market%20segment%20graph%20-%20Pharma%20other&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Pharma-other&v=1772595774035 "Future (projected) P/S market segment graph - Pharma other")
Future (projected) P/S of the market as a whole
Altamira Therapeutics develops drugs for the treatment of inner ear and upper respiratory tract diseases. The company operates in highly specialized healthcare niches. In the context of the overall revenue forecasts shown in the chart, Altamira represents a biotech with a targeted approach.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772595774056 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Altamira Therapeutics
Altamira Therapeutics is a biopharmaceutical company developing drugs for the treatment of inner ear and upper respiratory tract diseases. Its revenue, if reflected in the chart, likely comes from sales of Bentrio, a nasal spray designed to protect against allergens and viruses.
Sales of companies in the market segment - Pharma other
Altamira Therapeutics (CYTO) develops innovative therapies, including RNA-based therapies for viral infections and dizziness treatment. This metric reflects revenue within the pharmaceutical industry. Altamira's diversified portfolio addresses a variety of medical needs, from hearing protection to respiratory viruses.
Overall market sales
Altamira Therapeutics develops drugs for ear, nose, and throat diseases, as well as RNA-based therapies. Its development depends on clinical success and funding. This pattern of overall economic activity influences the investment climate. During favorable economic periods, investors are more willing to invest in biotech companies with innovative platforms.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Altamira Therapeutics
Altamira Therapeutics is a Swiss biotech company developing therapeutics for inner ear diseases, such as hearing loss and tinnitus, as well as viral infections. Future revenue depends on the success of its developments. This chart reflects analyst forecasts, which assess the potential of its innovative drug delivery platforms.
%20sales%20of%20the%20company%20Altamira%20Therapeutics&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Altamira-Therapeutics&v=1772595774352 "Schedule of future (projected) sales of the company Altamira Therapeutics")
Future (projected) sales of companies in the market segment - Pharma other
Altamira Therapeutics is a biopharmaceutical company developing drugs for the treatment of inner ear diseases and nasal sprays. The forecast in this chart reflects the potential future revenue from their product portfolio. This is an analyst's view of the market potential of their developments in otolaryngology.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Pharma%20other&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Pharma-other&v=1772595774398 "Schedule of future (projected) sales of companies in the market segment - Pharma other")
Future (projected) sales of the market as a whole
Altamira Therapeutics develops drugs to treat inner ear disorders (hearing loss, dizziness) and viral infections. The company targets areas with limited treatment options. This chart illustrates the overall investment climate, and Altamira's research progress is a bet on scientific breakthroughs in these complex and understudied areas of medicine.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772595774449 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Altamira Therapeutics
Altamira Therapeutics is a biopharmaceutical company developing RNA therapies for a variety of conditions, including hearing loss and allergies. Being at the forefront of science, it spends heavily on R&D. The chart shows its current return on investment in a breakthrough technology that could transform treatment approaches in the future.
Market segment marginality - Pharma other
Altamira Therapeutics is a biopharmaceutical company developing treatments for viral infections (Bentrio nasal spray) and hearing disorders. This chart reflects its path to commercial profitability. Success depends on sales of Bentrio and progress in developing other, more complex therapeutic programs.
Market marginality as a whole
Altamira Therapeutics develops drugs for the treatment of inner ear and upper respiratory tract diseases. As a development-stage company, it relies on external funding. This gross profitability chart reflects the investment climate. In a favorable economic environment, biotech companies find it easier to raise funds for clinical trials.
Employees in the company, segment and market as a whole
Number of employees in the company Altamira Therapeutics
Altamira Therapeutics is a Swiss biotech company developing drugs to treat inner ear disorders such as hearing loss and tinnitus. This chart shows the size of its research team, which is working to develop innovative treatments in this complex and underserved area of medicine.
Share of the company's employees Altamira Therapeutics within the market segment - Pharma other
Altamira Therapeutics is a biotech company developing RNA therapeutics for a variety of applications. During clinical trials, its most important resource is its scientific team. This chart illustrates the scale of the company's human capital investment in cutting-edge research to translate scientific discoveries into new treatments.
Number of employees in the market segment - Pharma other
Altamira Therapeutics is developing drugs to treat inner ear and upper respiratory tract diseases. This chart, reflecting employment in the pharmaceutical industry, provides a general overview. Altamira is focused on trends in otolaryngology, where the growing number of specialists and patients is creating demand for their innovative drug delivery methods, such as nasal sprays.
Number of employees in the market as a whole
Altamira Therapeutics is developing new treatments in areas such as ENT diseases and oncology. As with any development-stage biotech company, access to capital is vital. The growth in overall employment, reflected in this chart, signals a healthy economy, where investors are more willing to fund promising research.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Altamira Therapeutics (CYTO)
Altamira Therapeutics (CYTO) develops treatments in otology (ear diseases) and other niches. In this sector, market capitalization is rarely tied to headcount. This chart shows the value investors place on their R&D platform and patents. It's a classic example of a business where intellectual capital is valued far more than human capital.
%20of%20the%20company%20Altamira%20Therapeutics%20(CYTO)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Altamira-Therapeutics-CYTO&v=1772595774758 "Chart of market capitalization per employee (in thousands of dollars) of the company Altamira Therapeutics (CYTO)")
Market capitalization per employee (in thousands of dollars) in the market segment - Pharma other
Altamira Therapeutics develops drugs for the treatment of inner ear and nasopharyngeal diseases. In this narrow pharmaceutical niche, value is determined by the uniqueness of its developments. This indicator reflects how the market values its innovative treatment approaches, which can lead to high salaries per employee.
%20by%20market%20segment%20-%20Pharma%20other&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Pharma-other&v=1772595774779 "Market capitalization per employee (in thousands of dollars) by market segment - Pharma other")
Market capitalization per employee (in thousands of dollars) for the overall market
Altamira Therapeutics is a biopharmaceutical company developing drugs for the treatment of ear, nose, and throat diseases. Its projects are at various stages of research. This chart for Altamira illustrates how, in biotech, market capitalization per employee reflects the overall potential of the company's entire pipeline.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772595774824 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Altamira Therapeutics (CYTO)
Altamira Therapeutics is a biotech company working on RNA therapeutics. The company is in the R&D stage and is not generating revenue. This graph will show a negative value—the loss (investment) per research associate. This is typical for the industry, where years of research precede potential revenue.
%20Chart%20Altamira%20Therapeutics%20(CYTO)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Altamira-Therapeutics-CYTO&v=1772595774826 "Company Profit Per Employee (in thousands of dollars) Chart Altamira Therapeutics (CYTO)")
Profit per employee (in thousands of dollars) in the market segment - Pharma other
Altamira Therapeutics develops medications for ear, nose, and throat conditions, as well as antiviral sprays. In the pharmaceutical industry, targeting niche markets, the efficiency of research and development is crucial. This chart shows the team's financial productivity, which is an indicator of the company's ability to develop and commercialize its products.
%20in%20the%20market%20segment%20-%20Pharma%20other&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Pharma-other&v=1772595774827 "Chart of profit per employee (in thousands of dollars) in the market segment - Pharma other")
Profit per employee (in thousands of dollars) for the market as a whole
Altamira Therapeutics is a Swiss biotech company developing drugs for inner ear disorders (hearing loss, tinnitus), as well as antiviral sprays. This chart shows the average profitability of one employee in the economy. It provides investors with context: the biotech sector operates in an all-or-nothing paradigm, where the return on personnel (scientists) can be colossal if successful.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772595774852 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Altamira Therapeutics (CYTO)
Altamira Therapeutics is a biopharmaceutical company developing drugs for the treatment of inner ear and upper respiratory tract diseases. Its revenue per employee is generated primarily by sales of Bentrio nasal spray. The graph shows the initial commercialization of this product and its consumer adoption in various markets.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Altamira-Therapeutics-CYTO&v=1772595774855 "Sales chart per company employee Altamira Therapeutics (CYTO)")
Sales per employee in the market segment - Pharma other
Altamira Therapeutics (CYTO) is a company specializing in the development of nasal spray treatments for ear, nose, and throat conditions (e.g., hearing loss, allergies). This chart shows the average revenue per employee in the sector. It is important for assessing the effectiveness of R&D and commercialization compared to other pharmaceutical companies.
Sales per employee for the market as a whole
Altamira Therapeutics (CYTO) is a biopharmaceutical company developing RNA-based therapies, as well as sprays for protection against allergens and viruses (already commercialized). This metric reflects a hybrid model: it reflects the team's revenue generated from existing (but small) spray sales while simultaneously funding expensive R&D in the field of RNA therapeutics.
Short shares by company, segment and market as a whole
Shares shorted by company Altamira Therapeutics (CYTO)
Altamira Therapeutics (CYTO) is a Swiss biotech developing treatments for various conditions, including hearing loss and allergy sprays. This chart shows short interest. The high bearish bets may be due to the company's history of unsuccessful trials, frequent shifts in focus, and concerns about its ability to fund its diverse projects. (348)
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Altamira-Therapeutics-CYTO&v=1772595774895 "Short Shares Chart for the Company Altamira Therapeutics (CYTO)")
Shares shorted by market segment - Pharma other
Altamira Therapeutics (CYTO) develops therapeutic solutions for ear, nose, and throat (hearing loss, allergies) and viral defense (nasal sprays). The chart below shows the overall short position in the specialty pharmaceutical sector. It reflects the degree of skepticism among investors about the commercial potential of new drugs in these niches.
Shares shorted by the overall market
Altamira is a biotech with diversified R&D (from nasal sprays to hearing loss). This chart reflects the overall market pessimism. When investors are fearful, they dislike a "blurred" focus. They see R&D spending across multiple areas and fear that no project will take off before the company runs out of cash.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Altamira Therapeutics (CYTO)
Altamira Therapeutics (CYTO) is a Swiss company developing drugs for ear, nose, and throat conditions (hearing loss, allergies) and, most recently, antiviral sprays. This chart measures the rate of price change. It helps identify when the stock is "overheated" (above 70) on trial news or "oversold" (below 30) due to delays.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Altamira-Therapeutics-CYTO&v=1772595774953 "RSI 14 indicator chart for the company's stock Altamira Therapeutics (CYTO)")
RSI 14 Market Segment - Pharma other
Altamira Therapeutics is a Swiss biotech company developing drugs for the treatment of ear, nose, and throat diseases (hearing loss, allergies) and viral defense (nasal spray). This chart measures the overall momentum of the biotech sector. It helps separate CYTO volatility from the overall industry trend.
RSI 14 for the overall market
For Altamira Therapeutics, a biotech in R&D, this chart is a lifeline showing capital availability. During periods of market euphoria, investors are willing to "buy the dream" and fund breakthrough but risky research. When the market panics, the money supply is shut off, and cash-burning companies face a liquidity crisis.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast CYTO (Altamira Therapeutics)
Altamira Therapeutics is a Swiss biopharmaceutical company developing drugs for the treatment of inner ear disorders (tinnitus, hearing loss) and nasal sprays. This chart shows the speculative average price target from analysts, which is almost entirely dependent on their belief in the success of clinical trials of its R&D portfolio.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-CYTO-Altamira-Therapeutics&v=1772595775000 "A chart showing analyst consensus forecasts for the expected stock price. CYTO (Altamira Therapeutics)")
The difference between the consensus estimate and the actual stock price CYTO (Altamira Therapeutics)
Altamira is a biotech company focused on developing drugs to treat inner ear disorders (hearing loss, tinnitus). This chart shows the upside and downside potential analysts see in the stock. It measures the gap between the price and forecast, reflecting their confidence in this complex yet promising R&D pipeline.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-CYTO-Altamira-Therapeutics&v=1772595775003 "A chart showing the difference between the consensus forecast and the actual stock price. CYTO (Altamira Therapeutics)")
Analyst consensus forecast for stock prices by market segment - Pharma other
Altamira Therapeutics is a biotech company developing drugs (sprays) for the treatment of inner ear disorders (hearing loss, dizziness) and allergies. This chart shows analysts' overall expectations for the pharmaceutical sector. It reflects whether experts believe R&D success in this complex niche.
Analysts' consensus forecast for the overall market share price
Altamira Therapeutics is a Swiss biotech company specializing in the development of sprays for the treatment of ENT diseases (hearing loss, allergies). This chart reflects the overall market "risk appetite." For Altamira, a clinical-stage company, overall market optimism (risk appetite) is critical for attracting the capital needed to fund R&D.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Altamira Therapeutics
Altamira is a biotech R&D company that has rebooted itself. Their specialty is drug (RNA) delivery to non-hepatic tissues (i.e., outside the liver). This chart is a pure indicator of their R&D platform. It doesn't reflect revenue, but rather a speculative assessment of their (very risky) delivery technology and their chances of success in this hot R&D race.
AKIMA Market Segment Index - Pharma other
Altamira Therapeutics is a pharmaceutical company focused on ENT diseases. They develop sprays for viral protection, allergy treatment, and hearing restoration. This is a very specific pharmaceutical company. This chart compares their composite index to the sector, showing how their niche drugs outperform their competitors.
The AKIM Index for the overall market
Altamira Therapeutics is developing RNA therapeutics and nasal sprays (Bentrio) for protection against allergies and viruses. This chart, which reflects the market average, provides a macro backdrop. It helps assess how CYTO, which is shifting its focus to extrahepatic RNA delivery, compares to overall economic trends.
